Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH(R) Rapid PCR System

This study reports the development and validation of a rapid, automated, battery-operated PCR assay on the DASH(R) system that detects *Mycobacterium tuberculosis* from both sputum and tongue swabs with high sensitivity and specificity, making it suitable for point-of-care diagnosis in resource-limited settings.

The Gist

Imagine tuberculosis (TB) as a stealthy burglar hiding inside a house. For decades, doctors have tried to catch this burglar by asking patients to cough up "evidence" (sputum) from their lungs. But here's the problem: not everyone can cough up a sample, and sometimes the burglar is so well-hidden that the evidence is too small to find with old tools.

This paper introduces a new, high-tech "security system" designed to catch the TB burglar faster, easier, and in places where the power might flicker or the air conditioning doesn't work.

Here is the breakdown of their new invention, the DASH® MTB Test, using simple analogies:

1. The New "Sniffer Dog": Tongue Swabs

Traditionally, you need a deep cough (sputum) to find TB. But what if a patient is too weak to cough, or is afraid to spit?

• The Old Way: Asking someone to cough up a sample from deep in their lungs.
• The New Way: Just swab the back of the tongue, like checking a dog's mouth for a treat.
• Why it works: The TB bacteria (the burglar) often leaves "footprints" (DNA) on the tongue. The researchers found that swabbing the tongue is just as good as coughing up sputum for finding the disease, but it's much less scary and easier for the patient.

2. The "Burglar-Proof" Lysis Step

TB bacteria are tough. They have a thick, waxy armor that makes them impossible to break open with standard methods. It's like trying to crack a safe with a butter knife.

• The Solution: The researchers added a sonication step. Imagine putting the sample in a high-powered blender that vibrates so fast it shatters the bacteria's armor without damaging the DNA inside.
• The Result: Once the armor is broken, the test can easily grab the DNA evidence.

3. The "Magic Cartridge": The DASH System

The actual testing machine is called the DASH® Rapid PCR System. Think of this as a self-driving, all-in-one kitchen.

• How it works: You drop your tongue swab (or sputum) into a special, sealed cartridge. You pop the cartridge into the machine, and the machine does everything else automatically:
  1. It breaks the bacteria open.
  2. It hunts down the specific TB DNA (like a metal detector finding a specific coin).
  3. It amplifies the signal (turning a whisper into a shout) so it can be seen.
• Speed: In about 15 minutes, the machine gives a simple "Yes" or "No" answer on a screen. No waiting days for a lab result.

4. Built for the "Off-Grid" World

Most high-tech medical machines need a steady power supply, air conditioning, and a clean lab. This test was built for the real world, specifically for remote villages in developing countries.

• Battery Power: The machine can run on a portable battery (like a giant power bank), so it works even when the electricity goes out.
• Heat Resistant: The test cartridges are like "survival gear." They can sit in a hot room (up to 113°F / 45°C) for a whole year without going bad. You don't need a fridge to store them.
• No Contamination: The cartridge is a sealed box. Once the test is done, the dangerous genetic material is trapped inside, so it won't leak out and mess up the next test.

5. How Well Does It Work?

The researchers tested this on hundreds of people in South Africa.

• Accuracy: It caught the TB burglar 96% of the time when the bacteria were present in sputum, and 93% of the time when using tongue swabs.
• False Alarms: It rarely cried "wolf" when there was no danger (high specificity).
• Comparison: It performed just as well as the current "gold standard" test (GeneXpert), but it's faster and works on tongue swabs, which is a huge advantage.

The Big Picture

This paper describes a game-changer. By combining a tough "armor-breaking" step with a portable, battery-powered machine that can read a tongue swab, this test allows doctors in remote clinics to diagnose TB and start treatment on the same day a patient walks in.

Instead of a patient waiting weeks for a result and potentially getting sicker or spreading the disease, they can get a "Yes/No" answer in 15 minutes and start their medicine immediately. It's like upgrading from a slow, manual mail delivery to an instant text message for life-saving health news.

Technical Summary

1. Problem Statement

Tuberculosis (TB) remains the leading cause of death from a single infectious disease, with the majority of cases and deaths occurring in low- and middle-income countries (LMICs). Current diagnostic challenges include:

• Delayed Diagnosis: Centralized laboratory testing leads to significant delays in results, causing patients to be lost to follow-up and delaying treatment initiation.
• Sample Collection Barriers: Sputum is the gold standard specimen but is difficult to obtain from up to one-third of patients (especially children and HIV-positive individuals) who cannot expectorate.
• Infrastructure Limitations: Many peripheral healthcare settings lack consistent electricity, air conditioning, and specialized laboratory infrastructure required for complex molecular testing.
• Sample Complexity: Mycobacterium tuberculosis (MTB) has a waxy cell wall resistant to conventional lysis, and sputum contains high levels of PCR inhibitors and viscosity that interfere with nucleic acid amplification.

2. Methodology

The study developed and characterized a research-use-only (RUO) assay for the DASH® Rapid PCR System, a cartridge-based, automated, sample-to-answer platform.

Key Technical Components:

• Platform: The DASH system uses sequence-specific capture (SSC) to bind target DNA to paramagnetic particles, washing away inhibitors before amplification. It targets two multicopy MTB genomic regions: IS6110 and IS1081.
• Sample Types: Evaluated both sputum (collected on swabs) and tongue swabs (non-invasive, self-collectable).
• Pre-Analytical Optimization (Lysis): Since MTB is hard to lyse, the authors compared mechanical bead-beating/heat against sonication. Sonication was selected as the superior method for breaking down MTB cells and homogenizing viscous sputum.
  • Workflow: Specimen (swab) $\rightarrow$ 600 µL lysis buffer + glass beads $\rightarrow$ 3 minutes of sonication $\rightarrow$ Transfer to DASH cartridge $\rightarrow$ Automated extraction, amplification, and detection (14.5 min total run time).
• Controls: A synthetic DNA procedural control (PRC) monitors extraction efficiency and inhibitor presence.
• Validation Studies:
  • Analytical: Limit of Detection (LOD) using serial dilutions of MTB H37Ra; Specificity testing against 14 non-tuberculous mycobacteria (NTM) and other oral pathogens.
  • Clinical: Blinded testing of 100 sputum specimens and 110 tongue swab specimens from South African clinics. Results were compared against culture (gold standard) and Xpert Ultra.
  • Environmental: Cartridge stability at 45°C for one year and battery operation testing.

3. Key Contributions

• Dual-Sample Compatibility: Successfully adapted a high-sensitivity molecular assay to work with both sputum and tongue swabs, addressing the "sputum-less" patient population.
• Sonication Integration: Demonstrated that pre-cartridge sonication effectively lyses MTB and homogenizes sputum, overcoming viscosity and inhibitor issues without compromising the automated cartridge workflow.
• LMIC Suitability: Proved the system's robustness in resource-limited settings through:
  • Battery Operation: Successful operation for ~8.25 hours on a portable power station.
  • Thermal Stability: Cartridges remained stable and functional after 373 days at 45°C (simulating tropical climates without refrigeration).
  • Containment: The closed cartridge system prevents cross-contamination, eliminating the need for separate pre- and post-amplification rooms.

4. Key Results

Analytical Performance:

• Limit of Detection (LOD): 2.5 MTB cells per swab.
• Specificity: 100% (No cross-reactivity with 14 NTM strains or other common oral bacteria; no interference from high bacterial loads of non-target organisms).
• Linearity: The assay showed high linearity ($R^2 = 0.99$) and PCR efficiency (97.4%) across a wide range of sputum volumes and MTB concentrations.

Clinical Performance (vs. Culture/Xpert Ultra):

• Sputum Specimens (N=100):
  • Sensitivity: 96% (100% for smear-positive, 88% for smear-negative).
  • Specificity: 88%.
  • Performance was identical to Xpert Ultra. False positives were largely associated with "Trace" results and history of prior TB, suggesting detection of residual DNA or paucibacillary disease.
• Tongue Swab Specimens (N=110):
  • Sensitivity: 93% (compared to Xpert Ultra).
  • Specificity: 100%.
  • High sensitivity was maintained even for "Low" and "Very Low" bacillary loads (81% and 80%, respectively).

Operational Feasibility:

• Battery: Operated continuously for 33 tests (~8.25 hours) on a single portable power station.
• Stability: No performance degradation after one year at 45°C.
• Cross-Contamination: Zero cross-contamination observed when alternating high-positive and negative samples.

5. Significance

This study presents a viable solution for Near Point-of-Care (nPOC) TB diagnostics in resource-limited settings.

• Same-Day Diagnosis: The rapid turnaround time (~15 minutes) allows for treatment initiation during the first clinical encounter, breaking the cycle of loss to follow-up.
• Accessibility: By accepting tongue swabs, the test removes the barrier of sputum induction or expectoration, potentially diagnosing patients who would otherwise be missed.
• Infrastructure Independence: The combination of battery operation, heat-stable cartridges, and a closed-tube system makes this technology deployable in clinics without reliable electricity or advanced laboratory facilities.
• Alignment with WHO Targets: The assay meets or exceeds the World Health Organization's Target Product Profiles (TPP) for sensitivity in both sputum (85-90%) and non-sputum (75-80%) settings for nPOC and low-complexity tests.

Limitations & Future Work:
The authors note that the current procedural control (synthetic DNA) does not verify cell lysis efficiency, and the sonication step currently requires a prototype device. Future iterations will include a biological lysis control (spores) and a portable, battery-operated sonicator to fully enable use by untrained operators in the field.